PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Foslevodopa→

Foslevodopa PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
97321-87-4
Molecular formula
C9H12NO7P
Molecular weight
277.17 g/mol
Drug class
Levodopa prodrugdopamine precursor component of the foscarbidopa/foslevodopa combination
Mechanism of action
Foslevodopa is converted to levodopa, which crosses the blood-brain barrier and is decarboxylated to dopamine in the brain. It is administered with foscarbidopa to inhibit peripheral levodopa conversion and support continuous subcutaneous delivery.
Indications / reported uses
  • Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication

Sources: US DailyMed — VYALEV prescribing information · FDA product information — VYALEV · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Foslevodopa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Foslevodopa Permitted Daily Exposure (PDE) report (the Foslevodopa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Foslevodopa Occupational Exposure Limit (OEL) report (the Foslevodopa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.